Teva Pharmaceuticals is buying back the $3.5bn it paid out in cash for its stock
Teva is buying up its stock in its own company, making it one of the most valuable private companies in the world, after the pharmaceutical giant paid a $3bn cash settlement for insider trading.
The deal is part of a $20bn restructuring Teva announced last week to reduce its cash pile as it faces a global market slowdown.
Teva said it had paid out $3 billion to the US Securities and Exchange Commission (SEC) for insider information, including $3m to the SEC’s San Francisco office and $4.5m to a New York office for trading.
Tevac Pharmaceuticals, the company Teva bought from Valeant Pharmaceuticals in 2013 for $1.6bn, is also buying back its shares, making the total amount Teva paid to the regulator more than $5bn.
Teviac said in a statement it would be “conducting an orderly liquidation process”.
“We intend to return the $4bn Teva agreed to pay in cash to the Securities and Exchanges Commission for the purpose of paying off Teva’s outstanding obligations to shareholders,” it said.
Teva is one of several pharmaceutical companies in which the company paid out cash to settle insider-trading allegations. “
We will provide a public statement at the appropriate time regarding the settlement.”
Teva is one of several pharmaceutical companies in which the company paid out cash to settle insider-trading allegations.
Teva has been hit by several recent scandals, including allegations that it sold drugs to patients that had serious adverse events and failed to report the adverse events to regulators.
Tevo has been criticised for its lack of transparency and for having a poor track record of paying out compensation to its employees.
The company said that in 2014, the SEC approved Teva payouts of $2.5 million and $2m to shareholders of its US subsidiary.
Teava shares fell by as much as 20% in the wake of the SEC decision.
Teva, which is currently on the brink of bankruptcy, said it was pleased to see the deal come to fruition and that it would work closely with the SEC.